ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2448

Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission

Marie Moly1, Cédric Lukas 2, Jacques Morel 1, Bernard Combe 3 and Gaël Mouterde 4, 1CHU Montpellier, Montpellier, France, 2Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, 3CHU Montpellier, Montpellier University, Montpellier, France, 4CHU Montpellier and Univ Montpellier, Montpellier, France

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Disease Activity and remission, Psoriatic arthritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) requires evaluation of multiple aspects and can be difficult. Perception of disease activity by patient and physician is frequently discordant (1). The aim of our study was to evaluate factors associated with persistence of disease activity evaluated by patients yet considered in remission by their rheumatologist.

Methods: We performed a transversal monocentric study. PsA patients were included if they met the CASPAR criteria and if they were considered in remission by their rheumatologist. Demographic data, characteristics of the disease, treatments were collected. Disease activity was evaluated by several scores: Disease Activity Score (DAS28-CRP), Simple Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Disease Activity in Psoriatic Arthritis (DAPSA), Minimal Disease Activity (MDA), modified Boolean remission criteria for PsA. We collected multiple Patient’s Reported Outcomes (PROs): Psoriatic Arthritis Impact of Disease (PsAID), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Health Assessment Questionnaire (HAQ), Dermatology Life Quality Index (DLQI), Beck Depression Inventory (BDI), Fibromyalgia Rapid Screening Tool (FiRST), Pain Catastrophizing Scale (PCS). Discordance was defined by a difference between patient’s and rheumatologist’s global assessment ≥30/100 on a Visual Analogue Scale (VAS). Univariate and multivariate analyses were performed to evaluate factors associated with the presence of discordance.

Results: 62 PsA patients were included. 40.3 % were women and the mean (SD) age was 55 (14) years (Table 1). 61% patients were in remission (rheumatologist definition) for more than 12 months and 19% for less than 3 months. 50% met MDA, 63% DAS28-CRP < 2,6, 39% SDAI and CDAI remission, 27% DAPSA remission, and 8% Booleans remission criteria. 39% had a discordant disease activity assessment from their rheumatologist. In univariate analysis, factors associated with discordance were a history of depression, an associated fibromyalgia, a history of clinical enthesitis and a history of corticosteroid use (Table 2). All disease activity scores and PROs were higher in discordant group and were associated with discordance in univariate analysis. In multivariate analysis, discordance was associated with no previous corticosteroid use (OR 24.5 (95%CI 2.9-203.7), p=0.003), a higher BDI scale (OR 1.4 (95%CI 1.1-1.8) by supplementary point, p=0.017) and a higher DAPSA score (OR 1.5 (95%CI 1.2-2), p< 0.001) by supplementary point.

Conclusion: In this PsA cohort, discordance between patient and rheumatologist is very common. Discordance in assessment of disease activity was associated with no previous corticosteroid use, probably reflecting a less severe disease, presence of depressive symptoms and an increase of DAPSA, reflecting a more active disease.

Table 1: Demographic characteristics of the 62 PsA patients.

Table 2: Factors associated with discordance: Univariate analysis


Disclosure: M. Moly, None; C. Lukas, None; J. Morel, None; B. Combe, AbbVie, 5, BMS, 5, 8, Chugai, 5, 8, Eli Lilly, 5, Eli Lilly and Company, 5, 8, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 5, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche-Chugai, 5, 8, Sanofi, 5, UCB, 5, USD, 5; G. Mouterde, None.

To cite this abstract in AMA style:

Moly M, Lukas C, Morel J, Combe B, Mouterde G. Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-discordance-between-patient-and-rheumatologist-assessment-of-disease-activity-in-psoriatic-arthritis-considered-in-remission/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-discordance-between-patient-and-rheumatologist-assessment-of-disease-activity-in-psoriatic-arthritis-considered-in-remission/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology